Eli Lilly weight loss drug: Eli Lilly has introduced Mounjaro (tirzepatide), a weekly injectable medication for obesity and type 2 diabetes, in India after receiving approval from the Central Drugs Standard Control Organisation (CDSCO). Mounjaro is notable for its dual-action mechanism, targeting both GLP-1 and GIP receptors, which enhances its effectiveness in managing blood sugar levels.

While Ozempic is often prescribed off-label for weight loss, Mounjaro's approval specifically for obesity management positions it as a more targeted option.

Let's take a closer look at how these two medications compare in terms of efficacy, side effects, and usage.

What Are Mounjaro and Ozempic?